Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 107

1.

Life expectancy after initiation of combination antiretroviral therapy in Thailand.

Teeraananchai S, Chaivooth S, Kerr SJ, Bhakeecheep S, Avihingsanon A, Teeraratkul A, Sirinirund P, Law MG, Ruxrungtham K.

Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3121. [Epub ahead of print]

PMID:
28054931
2.

Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.

Durier N, Yunihastuti E, Ruxrungtham K, Kinh NV, Kamarulzaman A, Boettiger D, Widhani A, Avihingsanon A, Huy BV, Syed Omar SF, Sanityoso A, Chittmittrapap S, Dung NT, Pillai V, Suwan-Ampai T, Law M, Sohn AH, Matthews G.

J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630. [Epub ahead of print]

PMID:
27917597
3.

Application of Geriatric Principles and Care Models in HIV and Aging.

Sangarlangkarn A, Avihingsanon A, Appelbaum JS.

Interdiscip Top Gerontol Geriatr. 2017;42:119-133.

PMID:
27875828
4.

Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.

Prasithsirikul W, Chongthawonsatid S, Ohata PJ, Keadpudsa S, Klinbuayaem V, Rerksirikul P, Kerr SJ, Ruxrungtham K, Ananworanich J, Avihingsanon A; PROGRESS study team..

AIDS Care. 2016 Aug 10:1-7. [Epub ahead of print]

PMID:
27683949
5.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H.

Lancet HIV. 2016 Sep;3(9):e410-20. doi: 10.1016/S2352-3018(16)30016-9.

PMID:
27562742
6.

Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.

Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng OT, Kiertiburanakul S, Chaiwarith R, Kumarasamy N, Nguyen KV, Pham TT, Lee MP, Ditangco R, Merati TP, Choi JY, Wong WW, Kamarulzaman A, Yunihastuti E, Sim BL, Ratanasuwan W, Kantipong P, Zhang F, Mustafa M, Saphonn V, Pujari S, Sohn AH; TREAT Asia HIV Observational Databases (TAHOD)..

PLoS One. 2016 Aug 25;11(8):e0161562. doi: 10.1371/journal.pone.0161562.

7.

Improved adipose tissue function with initiation of protease inhibitor-only ART.

Maughan RT, Feeney ER, Capel E, Capeau J, Domingo P, Giralt M, Lange JM, Phanuphak P, Cooper DA, Reiss P, Mallon PW; HIVNAT-019 Study Group..

J Antimicrob Chemother. 2016 Nov;71(11):3212-3221.

8.

A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients.

Phuphanich M, Rattanamahattana M, Avihingsanon A, Chetchotisakd P, Putcharoen O, Gandhi M, Sohn AH, Imrie J, Phanuphak P, Kerr SJ.

J Virus Erad. 2016 Jan 1;2(1):22-7.

9.

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.

Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K; LASA Study Group..

Lancet HIV. 2016 Aug;3(8):e343-50. doi: 10.1016/S2352-3018(16)30010-8.

PMID:
27470026
10.

Differences Between Men Who Have Sex with Men (MSM) with Low CD4 Cell Counts at Their First HIV Test and MSM with Higher CD4 Counts in Bangkok, Thailand.

Sapsirisavat V, Phanuphak N, Sophonphan J, Egan JE, Langevattana K, Avihingsanon A, Friedman MR, Stall R; FAITH study team..

AIDS Behav. 2016 Dec;20(Suppl 3):398-407.

PMID:
27329100
11.

Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.

Sapsirisavat V, Vongsutilers V, Thammajaruk N, Pussadee K, Riyaten P, Kerr S, Avihingsanon A, Phanuphak P, Ruxrungtham K; PEDA study team..

PLoS One. 2016 Jun 20;11(6):e0157039. doi: 10.1371/journal.pone.0157039.

12.

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.

Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, Putcharoen O.

PLoS One. 2016 Apr 27;11(4):e0154221. doi: 10.1371/journal.pone.0154221.

13.

Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries.

Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration..

PLoS One. 2016 Apr 13;11(4):e0153243. doi: 10.1371/journal.pone.0153243.

14.

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group..

Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207.

PMID:
27048747
15.

Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.

Jiamsakul A, Kerr SJ, Ng OT, Lee MP, Chaiwarith R, Yunihastuti E, Van Nguyen K, Pham TT, Kiertiburanakul S, Ditangco R, Saphonn V, Sim BL, Merati TP, Wong W, Kantipong P, Zhang F, Choi JY, Pujari S, Kamarulzaman A, Oka S, Mustafa M, Ratanasuwan W, Petersen B, Law M, Kumarasamy N; TREAT Asia HIV Observational Database (TAHOD)..

Trop Med Int Health. 2016 May;21(5):662-74. doi: 10.1111/tmi.12690.

PMID:
26950901
16.

Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.

Audsley J, Bent SJ, Littlejohn M, Avihingsanon A, Matthews G, Bowden S, Bayliss J, Luciani F, Yuen L, Fairley CK, Locarnini S, Lewin SR, Sasadeusz J.

AIDS. 2016 Jun 19;30(10):1597-606. doi: 10.1097/QAD.0000000000001080.

PMID:
26950313
17.

The occurrence of Simpson's paradox if site-level effect was ignored in the TREAT Asia HIV Observational Database.

Jiamsakul A, Kerr SJ, Chandrasekaran E, Huelgas A, Taecharoenkul S, Teeraananchai S, Wan G, Ly PS, Kiertiburanakul S, Law M; TREAT Asia HIV Observational Database (TAHOD)..

J Clin Epidemiol. 2016 Aug;76:183-92. doi: 10.1016/j.jclinepi.2016.01.030.

PMID:
26854260
18.

Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.

Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M.

Lancet HIV. 2016 Jan;3(1):e13-22. doi: 10.1016/S2352-3018(15)00231-3.

PMID:
26762988
19.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team..

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908.

20.

Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.

Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K.

Drug Des Devel Ther. 2015 Oct 23;9:5763-9. doi: 10.2147/DDDT.S63989. Review.

Items per page

Supplemental Content

Loading ...
Support Center